Similar to generics, biosimilars offer the potential to change the landscape of the biopharma industry by bringing patients more access to medicines around the world and new revenue streams to the marketing authorization holders (MAHs) who bring these products to market. With many patents of branded biologics expiring, the biosimilars industry holds incredible growth potential, with a September 2015 report predicting revenues from such products will grow to US$26.5 billion by 2020, up from just US$2.5 billion in 2014. While biosimilars are approved as highly similar versions of already authorized biologics, MAHs will have to convince regulators, payers, physicians, and patients that they are as safe and effective as their originators when used in the real-world.